The K@W Network:
Does Aetna’s exit from Obamacare mean the program is failing? Not likely and other insurers seem satisfied, says a Wharton expert.
Mylan, the maker of the EpiPen allergy-treatment device, has raised outrage over out-sized price increases. Experts at Wharton and Penn Medicine explain the causes and the impact.
Steve Klasko, president of Thomas Jefferson University and CEO of the Jefferson System, says the health care industry needs be transformed and millennial consumers will lead the way.
North Star Alliance has built a network of health care clinics operating out of containers in Africa.
Could your doctor be ordering tests and treatments for you that don’t work very well and aren’t worth the cost? Experts from the Leonard Davis Institute of Health Economics discuss[…]
A new book by Andrea LaFountain, CEO of Mind Field Solutions, looks at the science of patient behavior to provide better health outcomes and cut health care costs.
The recent discovery of the first pan-drug resistant ‘superbug’ in the U.S. has alarmed the medical community. What are the possible solutions?
New research by Penn and Wharton finds that enrollment websites for the Affordable Care Act offer a wide variation of tools designed to help consumers pick the right health plan.
The federal government’s move to switch to value-based pricing of drugs for one category of public health plans could potentially have far-reaching effects, say experts.
Most U.S. employers have incentive programs designed to nudge workers toward better health. But according to Wharton’s David Asch, those programs don't adequately deal with the human element.